Beneficial effect of 7-O-galloyl-D-sedoheptulose on oxidative stress and hepatic and renal changes in type 2 diabetic db/db mice.
The aim of the present study was to evaluate the beneficial effects of 7-O-galloyl-D-sedoheptulose (GS), isolated from Corni Fructus, on hepatic and renal lipid metabolisms and advanced glycation endproduct formation followed by oxidative stress and inflammation using type 2 diabetic mice. GS was orally administered to db/db mice at doses of 20 and 100 mg/kg body weight per day for 8 weeks, and its effects were compared with those of the vehicle in db/db and m/m mice. The serum, hepatic, and renal biochemical factors, and protein expressions related to lipid metabolism, inflammation, advanced glycation endproducts, and their receptors, were measured. After 8 weeks of GS treatment, elevation of serum adiponectin as well as an improvement of hepatic and renal functional parameters was shown in db/db mice, and significant reductions of lipids in serum, liver, and kidney were observed according to the down-regulation of sterol regulatory element-binding protein-1. Moreover, GS inhibited oxidative stress and advanced glycation endproduct formation and their receptor expressions in the liver and kidney of db/db mice. These results suggest that GS could effectively inhibit advanced glycation endproduct formation caused by oxidative stress and/or dyslipidemia in the liver and kidney of db/db mice. Furthermore, the augmented expression of nuclear factor-kappa B p65 and its related inflammatory protein expressions were down-regulated in GS-treated groups. In conclusion, GS could have hepato- and reno-protective effects against abnormal lipid metabolism and the reactive oxygen species-related formation of advanced glycation endproducts with inflammation in type 2 diabetes.
Park
Chan Hum
CH
Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Noh
Jeong Sook
JS
Yamabe
Noriko
N
Kang
Ki Sung
KS
Tanaka
Takashi
T
Yokozawa
Takako
T
D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D004326:Drinking / Q000187:drug effects; D005786:Gene Expression Regulation / Q000187:drug effects; D005947:Glucose / Q000378:metabolism; D006403:Hematologic Tests; D006539:Heptoses / Q000494:pharmacology*; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D008297:Male; D051379:Mice; D009929:Organ Size / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects*; D014280:Triglycerides / Q000378:metabolism
C540464:7-O-galloyl-D-sedoheptulose; D015415:Biomarkers; D006539:Heptoses; D014280:Triglycerides; D002784:Cholesterol; D005947:Glucose